Acute respiratory distress syndrome without identifiable risk factors: A secondary analysis of the ARDS network trials

Abstract

Purpose: We examined whether patients with acute respiratory distress syndrome (ARDS) lacking risk factors are enrolled in therapeutic trials and assessed their clinical characteristics and outcomes.

Methods: We performed a secondary analysis of patient-level data pooled from the ARMA, ALVEOLI, FACTT, ALTA and EDEN ARDSNet randomized controlled trials obtained from the Biologic Specimen and Data Repository Information Coordinating Center of the National Heart, Lung and Blood Institute. We compared baseline characteristics and clinical outcomes (before and after adjustment using Poisson regression model) of ARDS patients with versus without risk factors.

Results: Of 3733 patients with ARDS, 81 (2.2%) did not have an identifiable risk factor. Patients without risk factors were younger, had lower baseline severity of illness, were more likely to have the ARDS resolve rapidly (i.e., within 24 h) (p < 0.001) and they had more ventilator-free days (median 21; p = 0.003), more intensive care unit-free days (18; p = 0.010), and more non-pulmonary organ failure-free days (24; p < 0.001) than comparators (17, 14 and 18, respectively). Differences persisted after adjustment for potential confounders.

Conclusions: Patients with ARDS without identifiable risk factors are enrolled in therapeutic trials and may have better outcomes, including a higher proportion of rapidly resolving ARDS, than those with risk factors.

Keywords: Acute lung injury; Acute respiratory failure; Epidemiology; Hypoxemia; Intensive care unit.

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Copyright © 2018 Elsevier Inc. All rights reserved.

Figures

Figure 1

Kaplan Meier curves of mortality of patients with acute respiratory distress syndrome with versus without identifiable risk factors (p=0.2 by log-rank test). Patients discharged home were considered alive at 60 days.